Skip to main content
News

FDA Issues Class II Recall for Sucralfate Tablets Manufactured by Nostrum Laboratories

Nostrum Laboratories, Inc has initiated a nationwide voluntary recall of its Sucralfate Tablets, USP 1 gram, due to significant concerns over product quality stemming from current good manufacturing practice (CGMP) deviations. The recall affects all lots within expiry and includes two packaging formats: 100-count bottles (NDC 29033-0003-01) and 500-count bottles (NDC 29033-0003-05). In total, 60 608 bottles of the drug are being pulled from shelves across the US. The recall, classified under recall number D-0547-2025, was initiated via press release on July 11, 2025, and is currently ongoing.

The US Food and Drug Administration (FDA) has classified the recall as Class II, indicating that exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote. The decision follows Nostrum Laboratories’ filing for Chapter 11 bankruptcy protection in September 2024, which left the company unable to maintain the necessary quality monitoring systems. As a result, the FDA deems the affected products adulterated, as they cannot be assured to meet their labeled identity, strength, quality, or purity characteristics.

Sucralfate is a prescription medication commonly used for the treatment and prevention of duodenal ulcers. It works by forming a protective barrier over ulcers, shielding them from stomach acid and allowing healing to occur. Pharmacists should advise patients on possible alternatives and consult healthcare providers for guidance regarding continued treatment, especially for those currently prescribed Sucralfate manufactured by Nostrum Laboratories.